BACKGROUND: Allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients are at high risk of complications associated with COVID-19 infection due to dysfunction of their immune system. Vaccination can protect from the adverse consequences of COVID-19. However, studies on the efficacy of COVID-19 vaccines in HSCT recipients with insufficient post-HSCT immune reconstitution are still scarce. In our study, we determined how immunosuppressive medication and the reconstitution of the cellular immune system influenced T cell responses specific for the surface glycoprotein of SARS-CoV-2 virus (S antigen) after two doses of mRNA vaccine against COVID-19 in patients with myeloid malignancies treated with HSCT. METHODS: Vaccination outcomes were followed in 18 (allo-HSCT) recipients and 8 healthy volunteers. The IgG antibodies against SARS-CoV-2 spike (S) and nucleocapsid (NCP) protein were determined in ELISA and S-specific T cells were detected using a sensitive ELISPOT-IFNγ based on in vitro expansion and restimulation of T cells in pre- and post-vaccination blood samples. Multiparametric flow cytometry analysis of peripheral blood leukocyte differentiation markers was employed for determination of reconstitution of the main subpopulations of T cells and NK cells at month 6 after HSCT. RESULTS: S- specific IgG antibody response detected in 72% of the patients was lower than in healthy vaccinees (100%). Vaccine-induced T-cell responses to S1 or S2 antigen were significantly reduced in HSCT recipients, which were treated with corticosteroids in dose 5 mg of prednisone- equivalents or higher during the vaccination period or in preceeding 100 days in comparison with recipients un-affected with corticosteroids. A significant positive correlation was found between the level of anti-SARS-Cov-2 spike protein IgG antibodies and the number of functional S antigen-specific T cells. Further analysis also showed that the specific response to vaccination was significantly influenced by the interval between administration of vaccine and transplantation. Vaccination outcomes were not related to age, sex, type of mRNA vaccine used, basic diagnosis, HLA match between HSC donor and recipient, and blood counts of lymphocytes, neutrophils, and monocytes at the time of vaccination. Multiparametric flow cytometry analysis of peripheral blood leukocyte differentiation markers showed that good humoral and cellular S-specific immune responses induced by vaccination were associated with well-reconstituted CD4+ T cells, mainly CD4+ effector memory subpopulation at six months after HSCT. CONCLUSIONS: The results showed that both humoral and cellular adaptive immune responses of HSCT recipients to the SARS-CoV-2 vaccine were significantly suppressed by corticosteroid therapy. Specific response to the vaccine was significantly affected by the length of the interval between HSCT and vaccination. Vaccination as early as 5 months after HSCT can lead to a good response. Immune response to the vaccine is not related to age, gender, HLA match between HSC donor and recipient, or type of myeloid malignancy. Vaccine efficacy was dependent on well-reconstituted CD4+ T cells, at six months after HSCT.

Department of Immunology Institute of Hematology and Blood Transfusion Prague Czech Republic

Department of Immunomonitoring and Flow Cytometry Institute of Hematology and Blood Transfusion Prague Czech Republic

Transplant Unit and Hematological Intensive Care Unit Institute of Hematology and Blood Transfusion Prague Czech Republic

See more in PubMed

Orchard K., Dignan F.L., Lee J., et al. The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact. Br. J. Haematol. 2021;192:467–473. PubMed PMC

Sharma A., Bhatt N.S., St, Martin A., et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185–e193. PubMed PMC

Mushtaq M.U., Shahzad M., Chaudhary S.G., et al. Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients. Transpl. Cell Ther. 2021;27:796.e1–796.e7. PubMed PMC

Ljungman P., de la Camara R., Mikulska M., et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. 2021;35:2885–2894. PubMed PMC

Chaekal O., Gomez-Arteaga A., Chen Z., et al. Predictors of Covid-19 vaccination response after In-Vivo T-cell-depleted stem cell transplantation. Transpl. Cell Ther. 2022;28:618.e1–618.e10. PubMed PMC

Ram R., Hagin D., Kikozashvilli N., et al. Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy-a single-center prospective cohort study. Transpl. Cell Ther. 2021;27:788–794. PubMed PMC

Lindemann M., Klisanin V., Thümmler L., et al. Humoral and cellular vaccination responses against SARS-CoV-2 in hematopoietic stem cell transplant recipients. Vaccin. (Basel) 2021;9:1075. doi: 10.3390/vaccines9101075. PubMed DOI PMC

Einarsdottir S., Martner A., Waldenström J., et al. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. Blood Adv. 2022;6:2723–2730. PubMed PMC

Murray S.M., Barbanti M., Campbell C., et al. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant. Br. J. Haematol. 2022;198:668–679. PubMed PMC

Harrington P., Doores K.J., Saha C., et al. Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients. Cancer Cell. 2021;39:1448–1449. PubMed PMC

Clémenceau B., Guillaume T., Coste-Burel M., et al. SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 mRNA vaccine. Vaccin. (Basel) 2022;10:448. doi: 10.3390/vaccines10030448. PubMed DOI PMC

Ljungman P. Guidelines for COVID-19 vaccination of The European Society for Blood and Marrow Transplantation (EBMT) (version 8.0).

Stastna-Markova M., Hamsikova E., Hainz P., et al. Pretransplant BK virus-specific T-cell-mediated immunity and serotype specific antibodies may have utility in identifying patients at risk of BK virus-associated haemorrhagic cystitis after allogeneic HSCT. Vaccin. (Basel) 2021:9. doi: 10.3390/vaccines9111226. PubMed DOI PMC

Vanikova S., Koladiya A., Musil J. OMIP-080: 29-color flow cytometry panel for comprehensive evaluation of NK and T cells reconstitution after hematopoietic stem cells transplantation. Cytom. A. 2022;101:21–26. PubMed PMC

Bosch M., Khan F.M., Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr. Opin. Hematol. 2012;19:324–335. PubMed

Painter M.M., Mathew D., Goel R.R., et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54:2133–2142. e3. PubMed PMC

Phetsouphanh C., Khoo W.H., Jackson K., et al. High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells. Front Immunol. 2022;13:1032911. PubMed PMC

Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT